NO SHOW JOBS 🤌

Thursday, April 16, 2026 | 9:00 AM PST

Your daily edge. The Consigliere delivers.

Market Snapshot

📊 Live Quotes — S&P Breaks Higher Again

S&P 500

7,036

▲ 0.18%

Nasdaq

24,086

▲ 0.29%

$AAPL

$262.62

▼ 1.43%

$AMZN

$247.70

▼ 0.32%

$HIMS

$26.44

▲ 8.83%

$TSM

$368.15

▼ 1.85%

$NET

$200.72

▲ 5.57%

$TSLA

$389.15

▼ 0.71%

Market Tone: S&P printing fresh highs at 7,036, Nasdaq at 24,086. Four days ago we told the family markets wanted to go higher. They are. HIMS ripping +8.83% confirms today's Bada Bing peptide thesis in real time. TSM down 1.85% is classic "sell the news" after a monster 58% profit jump beats, stock up 35% YTD and 137% over the trailing twelve months so some profit-taking is earned. NET up 5.57% on continuing cyber tailwinds. AAPL and AMZN softer today as the Amazon Leo integration story digests. And underneath the tape, the most underrated trade in pharma is quietly setting up for the next leg higher.

Bada Bing 🎯

Ozempic Was Just the Opening Act. Peptides Are the Show.

Three years ago, the word "peptide" was mostly confined to gym bros injecting BPC-157, bodybuilders talking about TB-500 in Reddit forums, and a handful of obscure biotech analysts who covered the segment. Today, peptides are the single largest growth vector in global pharma, and Wall Street is barely halfway done figuring that out.

Here's the number the family needs to see first. The global peptide therapeutics market was $140.86 billion in 2025. It's projected to reach $294.58 billion by 2033 at a 10.91% compound annual growth rate according to Fortune Business Insights. Other analyst shops put the 2034 figure north of $334 billion. Either way, that's a doubling of the market in less than a decade, and the curve is accelerating, not flattening.

For context, that growth rate puts peptides ahead of AI infrastructure spend, ahead of electric vehicle adoption, ahead of the cloud computing build-out. It's one of the fastest-growing verticals in any industry, and 99% of retail investors can't name three peptide stocks.

$334B by 2034

Global peptide therapeutics market. Up from $140.86B in 2025. 10.91% CAGR. Faster growth than AI infrastructure spend, EV adoption, or cloud computing buildout. Ozempic and Mounjaro alone cleared $50B in 2025 revenue, on pace for $100B by 2030.

Let me explain why this is happening, because the "so what" matters more than the headline.

Peptides are short chains of amino acids that the human body already uses to regulate almost everything. Insulin is a peptide. Growth hormone is a peptide. Oxytocin is a peptide. The drugs that came out of peptide research first were replacements for peptides the body already makes but can't produce enough of. Classic example: diabetics who can't make insulin.

The revolution is what happened next. Scientists figured out how to design peptides that do what natural peptides do, but better, longer, and with fewer side effects. Semaglutide (Ozempic, Wegovy) is the most famous example. It mimics a natural gut hormone called GLP-1 that tells your brain you're full. Novo Nordisk commercialized it. Eli Lilly commercialized a next-generation version called tirzepatide (Mounjaro, Zepbound) that hits two receptors instead of one. Between them, these two drugs generated more than $50 billion in combined revenue in 2025 and are on pace to hit $100 billion by 2030.

But here's what the family needs to understand. GLP-1 peptides for obesity are just the first wave. The pipeline behind them is enormous. Peptides are now being developed for oncology (bind directly to cancer cells and deliver cytotoxic payloads with minimal damage to healthy tissue). For autoimmune disease. For neurological disorders. For rare genetic conditions. For cardiovascular disease. The FDA has already approved more than 100 peptide therapeutics. Hundreds more are in clinical trials.

And AI is about to make this a flywheel.

Remember the Google DeepMind C2S-Scale story from Tuesday? That's the tip of the iceberg. OpenAI announced this week a formal partnership with Novo Nordisk, the maker of Ozempic, to deploy AI across Novo Nordisk's drug discovery and manufacturing. In January, Pepticom secured $6.6 million to advance AI-powered peptide drug discovery. Merck and Cyprumed entered a license agreement specifically for oral peptide development. AI plus peptides plus accelerating clinical success rates equals a drug discovery engine that generates new winners every quarter.

Here's the contrarian angle. The obvious trade is to buy Eli Lilly and Novo Nordisk and call it a day. Those are great companies and they'll win no matter what. But they're fully priced. The real asymmetric upside is in the layers underneath.

In December 2025, Reuters reported Eli Lilly is investing more than $6 billion to build a new active drug ingredient manufacturing facility in Huntsville, Alabama, specifically for peptide medicines including its oral GLP-1 drug orforglipron. That's the third such US peptide manufacturing site Lilly has announced in two years. Each dollar invested is projected to generate up to four dollars in local economic activity. This is a full-scale industrial build-out. And industrial build-outs create picks-and-shovels winners.

The family's peptide playbook lives in three layers.

Layer 1: The mega-caps that already own it. $LLY and $NVO. These are the GLP-1 kingmakers. They'll print money for years. Boring but bulletproof.

Layer 2: The delivery and distribution disruption. $HIMS ripping +8.83% today to $26.44. That is not a coincidence. HIMS has become the consumer-facing pure-play for peptide delivery, offering compounded semaglutide and related peptide treatments through its telehealth platform. Every time a peptide story breaks, HIMS moves. The stock is now being repriced as a peptide distribution business, not a telehealth company, and the valuation math works very differently under that thesis.

Layer 3: The AI-driven peptide discovery biotech layer. This is the lottery ticket tier. Rhythm Pharmaceuticals ($RYTM) with its rare disease peptide IMCIVREE. Ascendis Pharma ($ASND) with its TransCon peptide platform. Zealand Pharma. Apellis Pharmaceuticals. These names are volatile, speculative, and highly leveraged to clinical trial outcomes. You don't bet the farm on any single one. You build a small basket knowing that even one winner can deliver outsized returns.

The big one hiding in plain sight: OpenAI plus Novo Nordisk. This partnership is going to produce new peptide candidates at a pace pharmaceutical history has never seen. Every one of those candidates that advances to clinical trials is a potential billion-dollar drug. Novo Nordisk is already the most profitable pharma company on earth. This partnership is about to widen that moat by a country mile.

The bears will say peptides are a fad. Ozempic will fall out of favor. The GLP-1 market is saturated. Generic competition is coming. All of those takes miss the point. The peptide market is not about any single drug. It's about an entire new class of medicine that is structurally more effective, more targetable, and more scalable than small-molecule pharma has been for 50 years. The family is positioning before the rest of the market figures out the size of this.

Ozempic was the opening act. The show is about to start.

The family is watching. 🤌

📺 Watch today's breakdown on TikTok: tiktok.com/@noshowjobs

The Skim

Fact → So What → $Ticker

TSMC Reports 58% Profit Jump. Raises Full-Year Guidance. AI Chip Demand "Extremely Robust."

TSMC reported Q1 2026 net income of $18.11 billion, up 58% year-over-year, on revenue of $35.6 billion (+35% YoY). CEO C.C. Wei called AI chip demand "extremely robust" and raised full-year revenue growth guidance above 30%. Capex now guided toward the top of the $52-56 billion range. 3-nanometer chips now represent 25% of TSMC's total revenue, up from 6% in Q3 2023. TSM down 1.85% today to $368.15 is classic "sell the news" after a 137% trailing-12-month run, not a thesis change. Every NVIDIA GPU, every Apple Silicon, every Broadcom AI accelerator runs through this company.

Microsoft Ripped +5.23% Yesterday on Azure AI Breakthrough. Oversold Software Is Finally Bouncing.

MSFT closed at $413.65 yesterday, its biggest single-day gain of the year. The move was driven by an Azure AI infrastructure announcement that confirmed the bearish "AI will destroy SaaS" thesis was premature. Oracle, Salesforce, ServiceNow, and the rest of the software complex extended gains sympathetically. This ties directly to the Goldman Sachs "software oversold" call from earlier this week. MSFT reports earnings April 29. If Azure growth stabilizes above 30%, the stock re-rates aggressively higher.

Cloudflare Rips +5.57%. Cyber Infrastructure Thesis Catching Fire.

NET at $200.72 up 5.57% today, extending the cyber rebound from last week. Same thesis we called April 10 when CRWD was down 7% and PANW down 9%: agentic AI is expanding the attack surface, not shrinking it, and the picks-and-shovels cyber names are the beneficiaries. Jamie Dimon called cybersecurity "the largest risk JPMorgan faces" on Tuesday's earnings call. JPM is now testing Anthropic's Mythos AI which identified thousands of high-severity vulnerabilities in existing software. Cyber spend is accelerating, not slowing. The family's contrarian cyber call from last week is cooking.

Quantum Computing Stocks Just Had the Best Week in Years.

D-Wave (QBTS) closed up 22.63% Tuesday. IonQ (IONQ) surged 18% on the same day after announcing it had scaled its commercial systems beyond a single processor, a critical technical milestone. World Quantum Day on April 14 added fuel. The quantum thesis is quietly heating up in parallel with AI infrastructure, and the names with real revenue are separating from the pure-speculation tier. Speculative, but for the lottery-ticket sleeve of the portfolio, worth watching.

Waste Management 🗑️

The Bears Have Been Wrong About Every Megatrend for Three Years Running.

Let me run the tape.

In 2023, the bears said semiconductor stocks were a bubble. "Nobody needs this many GPUs." "Data center spend is peaking." "The AI hype is overdone." NVIDIA went from $150 to $500. The semi complex ran 80%.

In 2024, the bears said power infrastructure was overheated. "Utilities are boring." "Grid capex won't grow." "Nuclear is dead." The power ETF XLU gained 28%. Small modular reactor names ran 3-5x.

In 2025, the bears said nuclear restarts were a meme trade. "Vogtle was a disaster." "No one will ever build new nuclear." "Renewables will kill the thesis." Constellation Energy ran from $230 to $450. Vistra tripled.

Now, in 2026, the bears are coming for peptides. "Ozempic is a fad." "GLP-1 saturation is coming." "Weight loss is a phase." "Insurance won't cover these drugs long-term." You will hear every one of these takes on financial television this year.

Every one will be wrong.

Here's why. The bear case on peptides isn't based on science. It's based on pattern-matching to previous drug cycles where a blockbuster dominated for five years and then faced generic competition. That pattern doesn't apply here. Peptides are not a single drug. They are an entire new class of medicine with dozens of approved therapeutics, hundreds more in clinical trials, and an industrial manufacturing build-out that has already committed tens of billions of dollars in dedicated peptide production facilities. Eli Lilly alone is spending $6 billion in Huntsville on peptide manufacturing. That is not the behavior of a company preparing for a fad to end.

The family has seen this movie three times in three years. Semis, power, nuclear. Each time, the contrarian position was to front-run the megatrend before generalists caught up. Each time, the obvious companies delivered mega-cap returns while the picks-and-shovels names delivered even larger percentage gains.

The same setup is live right now in peptides. The obvious mega-caps ($LLY, $NVO) will compound at market-beating rates. The distribution disruptors ($HIMS) will re-rate as their thesis gets recognized. The AI-driven discovery biotechs will produce lottery-ticket winners that 10x or 20x if a trial reads positive.

The bears will be wrong again. The family is already positioned.

Cold tumors are turning hot. AI is writing the prescriptions. Peptides are the drugs it's writing. And the most important new class of medicine in 50 years is being built right now, in Huntsville and Indianapolis and Copenhagen, while the rest of the market argues about whether Microsoft will miss next quarter by a penny.

Ozempic was the opening act. The show is about to start.

The Family Ledger 📖

One Prediction. Timestamped. Immutable.

New Prediction

Peptide therapeutics becomes one of the top three narrative themes in healthcare investing for the next 18 months, alongside AI drug discovery and cell/gene therapy. $LLY compounds at above-market rates through 2027 as the peptide manufacturing build-out and orforglipron launch drive margin expansion. $NVO re-rates higher as the OpenAI partnership produces visible pipeline news. $HIMS trades above $32 within 120 days as the market formally reprices the stock from telehealth to peptide distribution. The broader peptide biotech basket (RYTM, ASND, ZEAL, and similar names) delivers at least one breakout name with a 3x+ return within 12 months on positive clinical data.

⚠️ Not investment advice. Do your own research. The family has positions in names mentioned.

🤖 Powered by AI. Edited by The Consigliere.

📧 Forward this to one trader you know. That's how the family grows. 🤌

noshowjobs.net · @NoShowJobs